After major setbacks to its existing COVID-19 vaccine platform, GSK is expanding its presence in mRNA, which increasingly looks to be the future.

Pfizer and BioNTech may be first out of the gate with robust results for a COVID-19 vaccine but amid all the excitement, Paul Hudson has issued a timely reminder that multiple vaccines will be needed to meet the huge demand.

Vaccine experts, including R&D leaders at Pfizer and Sanofi, describe what has been unique in developing a vaccine for the novel coronavirus, lessons learned from previous vaccines, and challenges that lie ahead.

Convalescent plasma has taken another battering as a potential treatment for coronavirus patients, after a UK drug safety body agreed with a US expert panel that there was not yet enough evidence to recommend its use in COVID-19 patients.